Brief Report

VOLUME: 36 | ISSUE: 1 | Mar 31, 2020 | PAGE: (8 - 9) | DOI: 10.24911/BioMedica/5-142

Cost of Fighting Against Hepatitis B and C in Pakistan to Rise above $3 Billion by 2030


Authors: Mehwish Khan


Authors

Mehwish Khan

Department of Mass Communication, University of Karachi, Karachi

Publication History

Received: December 28, 2019

Revised: February 16, 2020

Accepted: March 14, 2020

Published: March 31, 2020


Abstract


N/A


Keywords: Hepatitis B. Cost of Fighting


Pubmed Style

Mehwish Khan. Cost of Fighting Against Hepatitis B and C in Pakistan to Rise above $3 Billion by 2030. BioMedica. 2020; 31 (March 2020): 8-9. doi:10.24911/BioMedica/5-142

Web Style

Mehwish Khan. Cost of Fighting Against Hepatitis B and C in Pakistan to Rise above $3 Billion by 2030. https://biomedicapk.com/articles/online_first/142 [Access: April 28, 2024]. doi:10.24911/BioMedica/5-142

AMA (American Medical Association) Style

Mehwish Khan. Cost of Fighting Against Hepatitis B and C in Pakistan to Rise above $3 Billion by 2030. BioMedica. 2020; 31 (March 2020): 8-9. doi:10.24911/BioMedica/5-142

Vancouver/ICMJE Style

Mehwish Khan. Cost of Fighting Against Hepatitis B and C in Pakistan to Rise above $3 Billion by 2030. BioMedica. (2020), [cited April 28, 2024]; 31 (March 2020): 8-9. doi:10.24911/BioMedica/5-142

Harvard Style

Mehwish Khan (2020) Cost of Fighting Against Hepatitis B and C in Pakistan to Rise above $3 Billion by 2030. BioMedica, 31 (March 2020): 8-9. doi:10.24911/BioMedica/5-142

Chicago Style

Mehwish Khan. "Cost of Fighting Against Hepatitis B and C in Pakistan to Rise above $3 Billion by 2030." 31 (2020), 8-9. doi:10.24911/BioMedica/5-142

MLA (The Modern Language Association) Style

Mehwish Khan. "Cost of Fighting Against Hepatitis B and C in Pakistan to Rise above $3 Billion by 2030." 31.March 2020 (2020), 8-9. Print. doi:10.24911/BioMedica/5-142

APA (American Psychological Association) Style

Mehwish Khan (2020) Cost of Fighting Against Hepatitis B and C in Pakistan to Rise above $3 Billion by 2030. , 31 (March 2020), 8-9. doi:10.24911/BioMedica/5-142